Navigation Links
PathoGenetix Announces $10 Million Series C Financing

Woburn, MA (PRWEB) October 30, 2013

PathoGenetix™, Inc., a commercial-stage developer of an automated system for rapid bacterial identification, announced today that it has secured $10 million in a Series C financing to fund continued efforts to commercialize its Genome Sequence Scanning™ (GSS™) technology. The commitment was received from existing investors including Ascension Health Ventures, Excel Venture Management and HealthCare Ventures.

The GSS technology confirms and identifies microbial DNA in either complex mixtures or isolates, and provides actionable information in five hours. The funding will be used to further develop the first commercial system using the GSS technology, the RESOLUTION™ Microbial Genotyping System. The fully automated RESOLUTION System includes the instrument, bioinformatics software and database, and pathogen-specific assays, and will be commercially available in 2014 for use in food safety testing and foodborne illness outbreak investigations.

“This commitment from our investors reflects the outstanding progress we have made toward commercialization of the GSS technology. As we continue our efforts to deliver the RESOLUTION System for rapid pathogen strain typing, we also are gaining excellent market traction in the key public health and food industry sectors,” said Ann Merrifield, CEO of PathoGenetix.

The company announced collaborations with the Food and Drug Administration (FDA) in April and the U.S. Department of Agriculture’s Agricultural Research Service (USDA-ARS) in September, and is currently conducting a series of customer evaluations with leading food safety testing labs. In June, the company signed an agreement with Applied Maths, NV, to link the RESOLUTION System with the BioNumerics software suite currently in use in thousands of public and private research sites and laboratories around the world.

“We are excited about the potential for the GSS technology in a range of industrial, research and clinical applications,” said Tara Butler, MD, Managing Director at Ascension Health Ventures and PathoGenetix Board member. “PathoGenetix product development and research continue to demonstrate clear benefits for use in the food industry. We also believe the technology has significant potential in research and clinical applications such as microbiome analyses and genome mapping.”

Because GSS is culture independent and fully automated from sample preparation to final report, the technology greatly reduces the time, complexity, skill and cost required when compared to other molecular and next generation sequencing (NGS) identification approaches. The strain-type information provided by GSS is comparable to pulsed field gel electrophoresis (PFGE), the current standard for pathogen typing in foodborne outbreak investigation and response. As a result, GSS offers a powerful new tool for food industry pathogen traceback and public health epidemiological investigations, and can enable quicker decisions affecting food safety and public health.

About PathoGenetix, Inc.

PathoGenetix™, Inc. is a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. PathoGenetix is a venture-backed company that has received more than $50 million in technology development funding from the Department of Homeland Security. The core Genome Sequence Scanning™ (GSS™) technology analyzes DNA from an enriched biological sample—without the need for a cultured isolate—and provides results in five hours. GSS has broad applicability in food safety, industrial microbiology, and clinical diagnostics and research. The GSS technology will be available in the RESOLUTION™ Microbial Genotyping System in 2014 for use in food safety testing and foodborne illness outbreak investigations. Learn more at

About Ascension Health Ventures

Ascension Health Ventures ( was launched in 2001 as a wholly owned subsidiary of Ascension Health. Today it is a subsidiary of Ascension, a parent holding company formed in 2012. Ascension Health Ventures’ role has been to construct and manage a strategic portfolio of investments that deliver a venture investment return, have the potential to transform the healthcare industry and significantly enhance the experience for patients, their families and their caregivers. Ascension Health Ventures has three venture funds with $550 million in committed capital under management and its limited partners include Ascension, Catholic Health East, Catholic Health Initiatives, Decatur Memorial Hospital, Dignity Health, Intermountain Healthcare and Mercy.

About Excel Venture Management

Excel Venture Management builds companies that apply transformative technologies to solve problems in healthcare and beyond. The Excel investment portfolio is balanced across healthcare IT and services, diagnostics, and medical devices, plus life science platforms that address adjacent markets including energy, chemicals, defense and agriculture. Excel’s investments include leading companies such as Tetraphase Pharmaceuticals, Aileron Therapeutics, Cleveland Heart Lab, Synthetic Genomics, and IlluminOss. More information can be found at

About Health Care Ventures, LLC

HealthCare Ventures (HCV) is a leading life science venture capital firm. Since its founding in 1985, HealthCare Ventures has raised $1.6 billion in nine funds and has invested in 106 companies, 68 as startup ventures. The HCV team brings extensive, complementary experience both as investors and senior operating executives at biotechnology companies, and has had many notable successes in developing innovative pharmaceuticals and in achieving high value exits. More information can be found at


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. USDA-ARS and PathoGenetix to Evaluate Strain Typing System on Salmonella and E. coli
2. PathoGenetix to Present Strain Typing Technology and Research Results for Salmonella and Pathogenic E. coli at IAFP
3. PathoGenetix to Debut New Genotyping Technology for Rapid Strain Typing at IAFP
4. PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System
5. PathoGenetix Advances Commercialization of New RESOLUTION Microbial Genotyping System for Rapid Bacterial Serotyping and Strain Typing
6. PathoGenetix and FDA to Evaluate Bacterial Identification System for Use in FDA Public Health and Food Safety Efforts
7. PathoGenetix Adds Director of Manufacturing and Begins Production of New Rapid Bacterial Strain Typing System
8. PathoGenetix Hires Food Safety Testing Expert John W. Czajka as Vice President of Business Development
9. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
10. Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
11. MiMedx Announces Record Third Quarter Results
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio ... porcine and rodent control solutions , Bird ... oil, works across all sensory modalities including visual, smell, taste and touch, enabling safe, ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
Breaking Biology Technology:
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):